Fig. 2From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metforminPatient disposition; *One subject in the omarigliptin group participated in two clinical trials, in parallel, at two different sites. The subject is included in this diagram but excluded from all efficacy and safety analysesBack to article page